Quick Answer
Cardiff Oncology, Inc. reported Total Revenue of $593.0 thousand for the year ending 2025.
- Cardiff Oncology, Inc. showed a decrease of -13.2% in Total Revenue from 2024 to 2025.
- This data is from Cardiff Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $111.8 thousand | Q3 2018: $88.4 thousand | Q1 2019: $62.0 thousand | Q1 2019: $62.0 thousand | Q2 2019: $38.3 thousand | Q2 2019: $36.9 thousand | Q3 2019: $51.7 thousand | Q3 2019: $51.7 thousand | Q1 2020: $68.0 thousand | Q1 2020: $68.0 thousand | Q2 2020: $43.0 thousand | Q2 2020: $43.0 thousand | Q3 2020: $136.0 thousand | Q3 2020: $136.0 thousand | Q1 2021: $72.0 thousand | Q1 2021: $72.0 thousand | Q2 2021: $68.0 thousand | Q2 2021: $68.0 thousand | Q3 2021: $86.0 thousand | Q3 2021: $86.0 thousand | Q1 2022: $74.0 thousand | Q2 2022: $91.0 thousand | Q3 2022: $93.0 thousand | Q1 2023: $83.0 thousand | Q2 2023: $108.0 thousand | Q3 2023: $141.0 thousand | Q1 2024: $205.0 thousand | Q2 2024: $163.0 thousand | Q3 2024: $165.0 thousand | Q1 2025: $109.0 thousand | Q2 2025: $121.0 thousand | Q3 2025: $120.0 thousand.
- Over the full 9 years of available data (2018 to 2025), Cardiff Oncology, Inc.'s Total Revenue has grown by 56.7%.
- Historical annual values: Fiscal year 2025: $593.0 thousand | Fiscal year 2024: $683.0 thousand | Fiscal year 2023: $488.0 thousand | Fiscal year 2022: $386.0 thousand | Fiscal year 2021: $359.0 thousand | Fiscal year 2020: $366.0 thousand | Fiscal year 2020: $366.0 thousand | Fiscal year 2019: $244.6 thousand | Fiscal year 2018: $378.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: